Review
Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome
Chin Hee Kim, MD and Zobair M. Younossi, MD, MPH
Cleveland Clinic Journal of Medicine October 2008, 75 (10) 721-728;
Chin Hee Kim
Center for Liver Diseases–Inova Fairfax Hospital, Falls Church, VA
Zobair M. Younossi
Center for Liver Diseases–Inova Fairfax Hospital, Falls Church, VA
Executive Director of Research, Inova Health System
Professor of Medicine, Virginia Commonwealth University, Inova Campus

Article Information
vol. 75 no. 10 721-728
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online October 1, 2008.
Copyright & Usage
Copyright © 2008 The Cleveland Clinic Foundation. All Rights Reserved.
Cited By...
In this issue
Cleveland Clinic Journal of Medicine
Vol. 75, Issue 10
1 Oct 2008
Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome
Chin Hee Kim, Zobair M. Younossi
Cleveland Clinic Journal of Medicine Oct 2008, 75 (10) 721-728;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Machine Learning Enabled Non-invasive Diagnosis of Nonalcoholic Fatty Liver Disease and Assessment of Abdominal Fat from MRI Data
- Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot study
- {alpha}-Tocopherol bioavailability is lower in adults with metabolic syndrome regardless of dairy fat co-ingestion: a randomized, double-blind, crossover trial
- Potential for Dietary {omega}-3 Fatty Acids to Prevent Nonalcoholic Fatty Liver Disease and Reduce the Risk of Primary Liver Cancer
- Hyperinsulinemia Enhances Hepatic Expression of the Fatty Acid Transporter Cd36 and Provokes Hepatosteatosis and Hepatic Insulin Resistance
- Menhaden Oil Decreases High-Fat Diet-Induced Markers of Hepatic Damage, Steatosis, Inflammation, and Fibrosis in Obese Ldlr-/- Mice
- Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study
- Non-diabetic metabolic syndrome and obesity do not affect serum paraoxonase and arylesterase activities but do affect oxidative stress and inflammation